Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $180 | $182 | $159 | $146 |
| - Cash | $45 | $30 | $24 | $33 |
| + Debt | $231 | $202 | $173 | $144 |
| Enterprise Value | $365 | $354 | $308 | $257 |
| Revenue | $260 | $228 | $209 | $166 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Gross Profit | $95 | $81 | $73 | $70 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| EBITDA | $48 | $43 | $25 | $29 |
| % Margin | 18.5% | 19% | 11.9% | 17.8% |
| Net Income | $19 | $16 | $2 | $16 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS Diluted | 385.71 | 328.59 | 44.72 | 316.19 |
| % Growth | 17.4% | 634.8% | -85.9% | – |
| Operating Cash Flow | $23 | $8 | $3 | $22 |
| Capital Expenditures | -$31 | -$39 | -$30 | -$14 |
| Free Cash Flow | -$8 | -$31 | -$28 | $9 |